Effect of educational and policy interventions on institutional utilization of wet nebulization respiratory drugs and portable inhalers

Can J Clin Pharmacol. 2008 Summer;15(2):e334-43. Epub 2008 Sep 5.

Abstract

Background: Asthma and chronic obstructive pulmonary disease treatment guidelines support the preferential use of portable inhalers (PIs) over wet nebulization (WN) respiratory therapy. Hospital- and community-based educational initiatives and a community-based provincial drug program policy change were previously implemented to promote the conversion of WN therapy to PI and spacer device use in Nova Scotia.

Objective: To examine the effect of these interventions on salbutamol, ipratropium bromide, and spacer device (Aerochamber) use at the Queen Elizabeth II Health Sciences Centre (QEII HSC).

Methods: We conducted a time-series analysis of drug utilization data from August 1998 to July 2005. We used two intervention phases compared to the pre-intervention phase to determine whether the educational and policy interventions were associated with significant changes in monthly drug and spacer device utilization rates at the QEII HSC (1000-bed teaching hospital; Halifax, Nova Scotia).

Results: Salbutamol and ipratropium bromide PI use significantly increased in both intervention phases, compared to the pre-intervention phase. Mean (SD) defined daily doses/100 bed-days for salbutamol PI increased from 30.4 (0.4) in the pre-intervention phase to 34.6 (0.9) and 37.0 (0.4) in intervention phases I and II respectively (p<0.001 for both), and ipratropium bromide PI increased from 27.3 (3.5) to 32.8 (2.5) in intervention phase I (p=0.004) and 35.6 (3.5) in intervention phase II (p<0.001). However, a significant corresponding decrease was observed with salbutamol WN only. Mean (SD) Aerochamber units/100 bed-days significantly increased.

Conclusions: Educational and policy interventions had limited effects on converting WN to PI use at the QEII HSC.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Inhalation
  • Albuterol / economics
  • Albuterol / therapeutic use
  • Asthma / drug therapy
  • Asthma / economics
  • Bronchodilator Agents / economics
  • Bronchodilator Agents / therapeutic use
  • Health Services / economics
  • Health Services / statistics & numerical data*
  • Hospital Bed Capacity, 500 and over
  • Hospitals, Teaching
  • Humans
  • Inhalation Spacers / economics
  • Inhalation Spacers / statistics & numerical data*
  • Ipratropium / economics
  • Ipratropium / therapeutic use
  • Lung Diseases, Obstructive / drug therapy
  • Lung Diseases, Obstructive / economics
  • Nebulizers and Vaporizers / economics
  • Nebulizers and Vaporizers / statistics & numerical data
  • Nova Scotia
  • Patient Education as Topic*
  • Practice Guidelines as Topic*

Substances

  • Bronchodilator Agents
  • Ipratropium
  • Albuterol